This article is more than 5 years old. Information may no longer be current.
Porous, non-porous tantalum cups yielded similar septic, aseptic risks after revision THA
Click Here to Manage Email Alerts
BARCELONA, Spain — Use of porous tantalum cups after revision hip arthroplasty yielded low risks of septic and aseptic re-revision, which were similar to those obtained with non-porous tantalum cups, according to results presented at the EFORT Annual Congress.
Hemant G. Pandit, MBBS, MS(Orth), DNB(Orth), FRCS(Orth), DPhil(Oxon), Gulraj S. Matharu, MB ChB(Leeds), MRes(Birm), DPhil(Oxon), and colleagues received the EFORT Silver Orthopedics Free Paper Award for their research.
Using the National Joint Registry, Pandit and colleagues matched 1,931 patients who underwent revision hip arthroplasty with a porous tantalum cup (Trabecular Metal, Zimmer Biomet) to 1,931 patients who received a non-porous tantalum cup (Zimmer Biomet).
“The outcome of interest, as you would expect would be, was for re-revision for all-cause cup indications, aseptic loosening and infection,” Pandit said in his presentation.
Pandit noted an overall prevalence of acetabular re-revision rate of 2.7%, as well as no differences between the porous and non-porous tantalum cup groups when it came to 6-year implant survival for all-cause cup re-revision.
“If you look at [the] sub-hazard ratio, there was a 9% reduction with trabecular metal as compared to non-trabecular metal when it came to all cup re-revision,” Pandit said.
Although results showed no significant differences between porous and non-porous tantalum cups for aseptic loosening, Pandit noted the porous tantalum cups had a 32% higher chance of failing with aseptic loosening. He also noted no significant differences between the two groups with infection.
“Trabecular metal is porous. The bone grows quickly, therefore, infection rate is less,” Pandit said. “So the 6-year survival, again, no difference between the two; but if you look at sub-hazard ratio, [there’s a] 32% less chance of being re-revised after infection.” – by Casey Tingle
Reference:
Matharu G, et al. Paper 916. Presented at: EFORT Annual Congress; May 30-June 1, 2018; Barcelona, Spain.
Disclosure s : Pandit reports he receives research grants from Arthritis Research UK, The Orthopaedics Trust and the ROH Hip Research & Education Charitable Fund; has undertaken medicolegal work for Leigh Day as an expert advisor and for Kennedys Law as an expert witness; receives consultancy/lecture fees, honoraria and research grants from Servier, UK Renal Registry, Oxford Craniofacial Unit, IDIAP Jordi Gol, Freshfields Bruckhaus Deringer, Anthera Pharmaceuticals Inc. and Roche; received royalties from and is a consultant and speaker for Zimmer Biomet; receives research grants from Zimmer Biomet and Stryker; is a consultant for Zimmer Biomet, DePuy Synthes, BMS, Meril Life and Medacta; and receives research grants from Zimmer Biomet, Stryker and DePuy Synthes. The study was funded by Zimmer Biomet.